With Valchlor US win, Actelion to move forward on Ceptaris buy
This article was originally published in Scrip
Executive Summary
In bringing Valchlor (mechlorethamine) across the FDA finish line on 26 August, Ceptaris held up its end of a merger deal with Swiss drug maker Actelion, which late last month put up $25m to buy the Malvern, Pennsylvania-based specialty pharma, with a pledge to pay another $225m if certain other conditions were met, including having that US drug approval in hand.